Group 1 - The company, Zhongmu International (01822), announced a placement agreement to issue up to approximately 164 million shares at a price of HKD 0.10 per share, representing a discount of about 9.91% compared to the closing price of HKD 0.111 on the date of the agreement [1] - If the placement agent successfully sells all the shares, the company expects to raise a maximum net amount of approximately HKD 16.27 million, which will be used for further development of its food and beverage segment [1]

Group 1 - The company, Zhongmu International (01822), announced a placement agreement with a placement agent to issue up to approximately 164 million placement shares at a price of HKD 0.10 per share, representing a discount of about 9.91% compared to the closing price of HKD 0.111 on the date of the agreement [1] - If the placement agent successfully sells all the placement shares, the maximum net proceeds would be approximately HKD 16.27 million, which will be used for the further development of the company's food and beverage segment [1]

Group 1 - The company, Ocean Park Corporation, has completed the subscription agreement as of October 17, 2025, with all preconditions met, issuing 5.1 billion shares at a subscription price of HKD 0.45 per share, which represents approximately 62.85% of the existing issued share capital before completion and about 38.60% after completion [1] - After the completion of the subscription, Yu Faxiang will control 65.3% of the equity in Xiangyuan, which indirectly wholly owns the subscriber, holding 5.1 billion shares, accounting for 38.6% of the total issued shares [1] Group 2 - The net proceeds from the subscription are expected to be approximately HKD 2.284 billion, allocated as follows: about 20% (approximately HKD 456.8 million) for daily operations and working capital; about 40% (approximately HKD 913.6 million) for core business development, including theme park operations; and about 40% (approximately HKD 913.6 million) for repaying part of the existing debt, with 30% (approximately HKD 685.2 million) for bank and financial institution principal and interest repayment, and 10% (approximately HKD 228.4 million) for settling supplier payments and project-related debts [2] - Following the completion, several board members have resigned, including Qu Naijie as executive director, CEO, and chairman, with new appointments including Yu Faxiang as CEO and chairman, effective from October 17, 2025 [2]

Group 1 - The company announced a placement and subscription agreement, where the subscriber agreed to appoint a placement agent to facilitate the purchase of at least six subscribers at a price of HKD 0.476 per share for a total of 30.606 million shares [1] - The subscription price represents a discount of approximately 17.93% compared to the closing price reported on the stock exchange [1] - The subscriber is the company's chairman, executive director, and CEO, who beneficially owns 30,606,157 shares, accounting for about 17.14% of the total issued shares as of the announcement date [1] Group 2 - The maximum number of subscription shares is 30.606 million, representing approximately 17.14% of the company's existing share capital of 178,605,453 shares as of the announcement date [2] - The total gross proceeds from the subscription are expected to be approximately HKD 14.6 million, with a net amount of about HKD 14.2 million after deducting all relevant expenses [2] - The net proceeds are intended to be used for renovations of the Shanghai logistics center, procurement of new equipment, and general working capital for the group [2]

Core Viewpoint - The company, Shengbo Holdings (02340), has entered into a placement agreement to issue up to 127,448,000 shares at a price of HKD 0.137 per share, representing a discount of approximately 16.46% from the market price on the agreement date [1] Summary by Sections Placement Details - The placement is conditional and will be conducted through a placement agent, targeting at least six independent third-party professional investors or institutions [1] - If all shares are fully placed, the net proceeds are expected to be approximately HKD 16.87 million [1] Use of Proceeds - Approximately 29.64% of the proceeds will be allocated to pay professional fees, while about 70.36% will be used for the company's general working capital [1]

假设全部3782.54万股配售股份均获成功配售，配售所得款项总额将约为2.47亿港元，而配售所得款项净 额估计约为2.458亿港元。公司拟将所得款项净额用于以下用途：(i)9800万港元用于全球渠道布局及品 牌体系建设;(ii)9800万港元用于技术升级及供应链保障体系建设;(iii)4980万港元用于全球总部建设、全 球管理团队组建及其他一般营运开支。 上善黄金(01939)发布公告，于2025年9月29日，公司拟配售最多3782.54万股配售股份，相当于经悉数配 发及发行配售股份扩大后的已发行股份总数约7.03%。每股配售股份6.53港元的配售价，较9月29日收市 价每股8.150港元折让约19.88%。 ...

假设所有配售股份获悉数配售，净筹约5000万港元，拟用于清偿集团负债及用作集团一般营运资金。 小鱼盈通(00139)公布，于2025年9月26日，该公司拟透过配售代理向不少于六名承配人配售最多约2.05 亿股配售股份，配售价为每股配售股份0.25港元，较2025年9月26日在联交所所报收市价每股0.280港元 折让约11%。 ...

假设所有配售股份获悉数配售，净筹约5000万港元，拟用于清偿集团负债及用作集团一般营运资金。 智通财经APP讯，小鱼盈通(00139)公布，于2025年9月26日，该公司拟透过配售代理向不少于六名承配 人配售最多约2.05亿股配售股份，配售价为每股配售股份0.25港元，较2025年9月26日在联交所所报收市 价每股0.280港元折让约11%。 ...

Group 1 - The company, Sanofi Pharmaceutical-B (02257.HK), announced a subscription agreement to issue 17.3524 million shares at a subscription price of HKD 12.00 per share [1] - The total shares to be issued represent approximately 16.50% of the company's existing issued share capital and about 14.16% of the enlarged issued share capital after the issuance [1] - The subscription price of HKD 12.00 per share reflects a discount of approximately 19.84% compared to the closing price of HKD 14.97 on September 5, the last trading day before the agreement [1] Group 2 - The total proceeds from the subscription are expected to be approximately HKD 208.2 million, with net proceeds around HKD 206 million [1] - The company plans to use the proceeds from the subscription for general working capital [1] - The subscribers include Huaxi Biotechnology (Hong Kong) Co., Ltd., Mr. Xie Shuohao, Bamboo Bloom Limited, and Capstone Resources Holding Limited [1]

Core Viewpoint - WuXi AppTec (02268) has entered into a placement agreement to issue up to 22.277 million shares at a price of HKD 58.85 per share, potentially raising approximately HKD 1.311 billion in total proceeds [1] Group 1: Placement Details - The placement is conditional and will be conducted through a placement agent to at least six independent third-party investors [1] - If fully subscribed, the net proceeds from the placement are expected to be around HKD 1.301 billion [1] Group 2: Use of Proceeds - Approximately 90% of the proceeds will be allocated to expanding the company's service capabilities and production capacity, including clinical and commercial production of antibody-drug conjugates and active pharmaceutical ingredients [1] - The remaining 10% will be used for working capital needs and general corporate purposes [1]